1776 recently welcomed Horizon Pharmaceuticals to the Pennovation Center to discuss the impact of rare diseases on pharmaceutical innovation. Moderated by Carter McClure, Managing Director of the Pennovation Center, the evening's panel dealt with questions and challenges regarding the rare diseases that affect 30 million patients in the US. Panelists offered thoughts on how stakeholders in the rare disease community must work together to close the innovation gap and address unmet medical needs for patients.
